Vorasidenib Synthesis Using Stable Intermediates Without POCl3
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing vorasidenib at an industrial scale face safety concerns due to the instability of intermediates and the use of toxic reagents like POCl3, and harsh conditions that pose explosion risks, making them unsuitable for large-scale production.
Innovation Solution
A process involving the reaction of (R)-1,1,1-trifluoropropan-2-amine hydrochloride with sodium dicyanamide in specific solvents at controlled temperatures, followed by reaction with methyl 6-chloropyridine-2-carboxylate in the presence of a base, to yield vorasidenib, using safer and more stable intermediates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If existing methods use POCl3 and harsh conditions to prepare vorasidenib, then the reaction proceeds efficiently, but safety hazards increase due to toxicity and explosion risks
Solution Approach 1:
The patent changes the chemical parameters by replacing POCl3 with a two-step sequence using dicyanamide and trifluoropropan-2-amine hydrochloride. This substitution maintains reaction efficiency while eliminating the toxicity and explosion risks associated with POCl3, directly resolving the safety hazard issue.
Solution Approach 2:
The patent introduces intermediate compounds (dicyanamide and trifluoropropan-2-amine hydrochloride) as mediators to achieve the desired chemical transformation. These intermediates enable the reaction to proceed efficiently without requiring the hazardous POCl3 reagent, thus resolving the contradiction between productivity and safety.
2Device complexity
If existing methods use unstable intermediates for vorasidenib preparation, then the synthesis pathway is shorter, but reliability decreases due to storage and handling issues
Solution Approach 1:
The patent employs intermediates that are stable enough for practical handling and storage, replacing the previously used unstable intermediates. This allows the synthesis pathway to remain efficient while ensuring reliability in storage and handling operations.
3Loss of time
If existing methods use harsh reaction conditions to prepare vorasidenib, then the reaction completes faster, but safety risks increase due to explosion potential
Solution Approach 1:
The patent modifies the reaction conditions by replacing the harsh single-step POCl3 method with a two-step sequence using milder reagents. This maintains acceptable reaction speed while eliminating the explosion risk associated with harsh conditions, resolving the contradiction between time efficiency and safety.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process allows for the safe and efficient production of vorasidenib at an industrial scale with improved yield and reduced safety hazards, minimizing the number of reaction steps and avoiding the use of highly toxic reagents.
Implementation Method 1
reacting the compound of formula (III) with methyl 6-chloropyridine-2-carboxylate to yield vorasidenib
Data Source
AI summary
Process for the preparation of vorasidenib using N,N′-bis[(2R)-1,1,1-trifluoropropan-2-yl]triimidodicarbonic diamide hydrochloride